Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
Rhea-AI Summary
Beta Bionics (Nasdaq: BBNX) reported second quarter 2026 net sales of $32.0 million, a 38% increase from $23.2 million a year earlier, driven by 153% growth in the Pharmacy Benefit Plan (PBP) channel to $11.6 million and 9% growth in the DME channel to $20.4 million.
Gross margin improved to 59.0%, up 524 basis points year over year. The company recorded a net loss of $23.4 million (negative 73% of sales) versus $16.9 million, and adjusted EBITDA of negative $17.7 million versus negative $14.5 million. Cash, cash equivalents, and investments totaled $225.2 million at June 30, 2026. For full year 2026, Beta Bionics maintained revenue guidance of $131–$136 million, kept PBP new-start mix guidance unchanged, and raised gross margin guidance to 58.5–59.5%. The company also initiated a pivotal U.S. trial of iLet in adults with type 2 diabetes and outlined plans to fully commercialize its Mint patch pump by the end of the second quarter of 2027, both subject to FDA clearance.
Positive
- Net sales +38% YoY to $32.0 million in Q2 2026
- PBP channel net sales +153% YoY to $11.6 million
- Gross margin improved to 59.0%, up 524 basis points YoY
- Raised 2026 gross margin guidance to 58.5–59.5%
- Strong liquidity with $225.2 million in cash and investments
- New patient starts grew at least 10% sequentially in Q2 2026
Negative
- Net loss widened to $23.4 million from $16.9 million YoY
- Loss from operations $25.6 million, equal to negative 80% of sales
- Adjusted EBITDA loss increased to $17.7 million from $14.5 million
- Operating expenses rose to $44.5 million from $32.4 million YoY
- Stockholders’ equity declined to $256.4 million from $287.6 million at year-end 2025
News Explained
The completed second-quarter report shows Beta Bionics had 44,981,606 common shares issued and outstanding as of
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 21 | Q1 earnings report | Positive | -0.6% | Revenue growth and raised full-year guidance accompanied a negative 24-hour reaction. |
| Feb 17 | FY2025 earnings report | Positive | -2.6% | Strong annual growth and 2026 guidance accompanied a negative 24-hour reaction. |
| Jan 08 | Q4 topline update | Positive | -37.0% | Preliminary sales and user growth preceded a negative 24-hour reaction. |
| Dec 08 | Earnings scheduling notice | Neutral | -3.6% | The planned results release and investor meetings preceded a negative 24-hour reaction. |
| Oct 28 | Q3 earnings report | Positive | +10.3% | Quarterly growth and raised annual guidance accompanied a positive 24-hour reaction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
BBNX earnings-related announcements historically showed negative reactions in four of five tag-specific events despite generally positive operating updates.
Key Terms
adjusted ebitda financial
gaap financial
pharmacy benefit plan financial
fda form 483 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2026 and updated its full year guidance for the year ending December 31, 2026.
Second Quarter 2026 Financial Highlights & Key Metrics
- Net sales of
$32.0 million , up38% compared to$23.2 million in the second quarter of 2025.- Durable Medical Equipment (DME) channel net sales of
$20.4 million , up9% compared to$18.6 million in the second quarter of 2025. - Pharmacy Benefit Plan (PBP) channel net sales of
$11.6 million , up153% compared to$4.6 million in the second quarter of 2025.
- Durable Medical Equipment (DME) channel net sales of
- Gross margin of
59.0% , up 524 basis points compared to53.8% in the second quarter of 2025. - New patient starts increased by at least
10% but less than20% sequentially versus the first quarter of 2026.69% of new patient starts came from multiple daily injections (MDI).- High 30s percentage of new patient starts reimbursed through the PBP channel.
- Loss from operations of
$25.6 million , or negative80% of sales, compared to$19.9 million or negative86% of sales in the second quarter of 2025. - Net loss of
$23.4 million , or negative73% of sales, compared to$16.9 million or negative73% of sales in the second quarter of 2025. - Adjusted EBITDA(1) of negative
$17.7 million , or negative55% of sales, compared to negative$14.5 million or negative63% of sales in the second quarter of 2025. $225.2 million in cash, cash equivalents, short and long-term investments as of June 30, 2026.
(1) See “Non-GAAP Financial Measures” below for additional information. A reconciliation of the non-GAAP financial measure to its most directly comparable GAAP financial measure can be found in Table D.
Recent Strategic Highlights
- In July, initiated enrollment for a pivotal trial studying the iLet in adults with type 2 diabetes in the U.S.
- Beta Bionics expects to expand iLet’s indications for use to adults with type 2 diabetes in the U.S. around mid-year 2027, subject to regulatory clearance by the FDA.
- Announced updated expectations to fully commercialize Mint, Beta Bionics’ patch pump in development, by the end of the second quarter of 2027, subject to regulatory clearance by the U.S. Food and Drug Administration (FDA).
- The company expects Mint manufacturing capacity to meet anticipated demand at full launch.
- Published a near real-time real-world data dashboard publicly available on the company’s website, setting a new standard for data transparency in the Automated Insulin Delivery category.
- In its most recent Phase 2a feasibility trial in New Zealand initiated in the first quarter of 2026 for the bihormonal system in development, the company identified opportunities to improve the glucagon asset’s excipient profile and the bihormonal dosing algorithm, with improvements expected to take less than one year prior to initiating additional feasibility trials.
2026 Full Year Guidance
- Estimated total revenue of approximately
$131 million to$136 million (no change versus previous guidance). - Estimated
37% to39% of new patient starts reimbursed through the PBP channel (no change versus previous guidance). - Estimated gross margin of
58.5% to59.5% (previously57.5% to59.5% ).
Webcast & Conference Call Details
Beta Bionics will host a conference call and concurrent webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s second quarter 2026 performance. The link to the webcast will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following link, which will provide you with dial-in details and a personal pin: https://register-conf.media-server.com/register/BI3bd9f03fbd0f42bcb9f566c242240033
Non-GAAP Financial Measures
Beta Bionics, Inc. (the “Company”) prepares and presents the Company’s financial statements in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The Company believes adjusted EBITDA as a non-GAAP measure is useful in evaluating the Company’s operating performance and uses adjusted EBITDA to evaluate ongoing operations and for internal planning and forecasting purposes. The Company believes that this non-GAAP financial measure, when taken together with the corresponding GAAP financial measures, provide meaningful supplemental information regarding the Company’s performance by excluding certain items that may not be indicative of the Company’s business, results of operations, or outlook. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in the Company’s industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of the Company’s non-GAAP financial measures as tools for comparison. A reconciliation is provided below for adjusted EBITDA to the most directly comparable financial measure stated in accordance with GAAP in Table D below.
The Company calculates adjusted EBITDA as net loss adjusted to exclude (i) depreciation expense, (ii) stock-based compensation expense, (iii) interest income, (iv) income tax expense, (v) change in fair value of warrant liabilities, (vi) litigation settlement and other related expense, and (vii) quality system remediation (previously labeled “Other non-recurring” in the Form 10-K for the year ended December 31, 2025), which relates to one-time remediation efforts in response to the FDA Form 483 and Warning Letter, including contractor support and various updates to the quality system.
Some of the limitations of adjusted EBITDA include: (i) adjusted EBITDA does not properly reflect capital commitments to be paid in the future and (ii) although depreciation and amortization expense are non-cash charges, the underlying assets may need to be replaced and adjusted EBITDA does not reflect these capital expenditures. The Company’s adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate adjusted EBITDA in the same manner as the Company calculates the measure, limiting its usefulness as a comparative measure. In evaluating adjusted EBITDA, you should be aware that in the future the Company will incur expenses similar to the adjustments in this presentation. The Company’s presentation of adjusted EBITDA should not be construed as an inference that the Company’s future results will be unaffected by these expenses or any unusual or non-recurring items. When evaluating the Company’s performance, you should consider adjusted EBITDA alongside other financial performance measures, including the Company’s net loss and other GAAP results.
Investors are encouraged to review the related GAAP financial measures and the reconciliation of this non-GAAP financial measure to its most directly comparable GAAP financial measure, and not to rely on any single financial measure to evaluate the Company’s business. This non-GAAP measure has limitations as an analytical tool and should not be construed as an inference that the Company’s future results will be unaffected by unusual or non-recurring items. Therefore, this non-GAAP financial measure should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Beta Bionics, Inc. (the “Company”) regarding its clinical and regulatory development plans for the iLet and other product candidates; the markets and market opportunities for the iLet, Mint, the bihormonal system and other product candidates, if approved; the timing, likelihood or success of its business strategy, including commercialization as well as plans and objectives of management for future operations; its anticipated growth and other measures of future operating results and financial performance, including 2026 full year guidance regarding estimates of revenue, new patient starts reimbursed through the PBP channel and gross margin; the design, results, and timing of its research and development efforts and planned trials for the iLet in adults with type 2 diabetes; the design, results and timing of its research and development efforts and feasibility trials for the bihormonal system in development, including the expected timelines with respect to improvements to the glucagon asset’s excipient profile and the bihormonal dosing algorithm; and the timing or certainty of the FDA’s approval of Mint, the timing or certainty of the commercialization of Mint and related updates and the Company’s manufacturing capacity at launch. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties, including business, regulatory, economic and competitive risks and uncertainties about the Company, including, without limitation, risks inherent in developing product candidates, future results from the Company’s ongoing and future studies and clinical trials, the Company’s ability to obtain adequate financing to fund its product development and other expenses, risks that real-world data or future results may not be consistent with interim, initial or preliminary results or results from prior preclinical studies or clinical trials, trends in the industry, the Company’s relationships with its existing and future collaboration partners, the legal and regulatory framework for the industry, future expenditures and the potential impacts of global macroeconomic conditions. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. Other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission, including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
| Beta Bionics, Inc. | ||||||||||||||||
| Statements of Operations and Comprehensive Loss (unaudited) | ||||||||||||||||
| Table A | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| (In thousands, except number of shares and per share data) | June 30, | June 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net sales | $ | 32,013 | $ | 23,238 | $ | 59,639 | $ | 40,877 | ||||||||
| Cost of sales | 13,111 | 10,735 | 24,300 | 19,403 | ||||||||||||
| Gross profit | 18,902 | 12,503 | 35,339 | 21,474 | ||||||||||||
| Gross margin | 59.0 | % | 53.8 | % | 59.3 | % | 52.5 | % | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 10,240 | 8,873 | 20,596 | 16,463 | ||||||||||||
| Sales and marketing | 24,640 | 15,623 | 45,375 | 29,025 | ||||||||||||
| General and administrative | 9,600 | 7,879 | 19,217 | 14,500 | ||||||||||||
| Total operating expenses | 44,480 | 32,375 | 85,188 | 59,988 | ||||||||||||
| Loss from operations | (25,578 | ) | (19,872 | ) | (49,849 | ) | (38,514 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 2,177 | 3,005 | 4,553 | 5,441 | ||||||||||||
| Other expense | (2 | ) | (2 | ) | (2 | ) | (2 | ) | ||||||||
| Change in fair value of warrant liabilities | — | — | — | (12,450 | ) | |||||||||||
| Total other income (expense), net | 2,175 | 3,003 | 4,551 | (7,011 | ) | |||||||||||
| Net loss | $ | (23,403 | ) | $ | (16,869 | ) | $ | (45,298 | ) | $ | (45,525 | ) | ||||
| Other comprehensive income (loss): | ||||||||||||||||
| Unrealized gain (loss) on short-term and long-term investments | (294 | ) | (91 | ) | (793 | ) | 84 | |||||||||
| Comprehensive loss | $ | (23,697 | ) | $ | (16,960 | ) | $ | (46,091 | ) | $ | (45,441 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.53 | ) | $ | (0.39 | ) | $ | (1.02 | ) | $ | (1.23 | ) | ||||
| Weighted-average common shares outstanding, basic and diluted | 44,545,293 | 43,390,652 | 44,554,141 | 37,087,726 | ||||||||||||
| Beta Bionics, Inc. | ||||||||||||||||
| Balance Sheets (unaudited) | ||||||||||||||||
| Table B | ||||||||||||||||
| (In thousands, except number of shares) | June 30, | December 31, | ||||||||||||||
| 2026 | 2025 | |||||||||||||||
| Assets | ||||||||||||||||
| Current assets: | ||||||||||||||||
| Cash and cash equivalents | $ | 44,318 | $ | 31,576 | ||||||||||||
| Restricted cash, current | 100 | 100 | ||||||||||||||
| Short-term investments | 136,171 | 187,549 | ||||||||||||||
| Accounts receivable, net | 18,053 | 17,118 | ||||||||||||||
| Inventories | 23,918 | 21,722 | ||||||||||||||
| Prepaid expenses and other current assets | 8,474 | 9,840 | ||||||||||||||
| Total current assets | 231,034 | 267,905 | ||||||||||||||
| Property and equipment, net | 10,748 | 8,600 | ||||||||||||||
| Operating lease right-of-use asset | 5,816 | 6,627 | ||||||||||||||
| Long-term investments | 44,648 | 45,431 | ||||||||||||||
| Other long-term assets | 141 | 180 | ||||||||||||||
| Total assets | $ | 292,387 | $ | 328,743 | ||||||||||||
| Liabilities and Stockholders’ Equity | ||||||||||||||||
| Current liabilities: | ||||||||||||||||
| Accounts payable | $ | 5,351 | $ | 4,998 | ||||||||||||
| Accrued expenses and other current liabilities | 17,194 | 22,431 | ||||||||||||||
| Operating lease liabilities | 1,591 | 1,938 | ||||||||||||||
| Deferred revenue | 1,881 | 1,557 | ||||||||||||||
| Total current liabilities | 26,017 | 30,924 | ||||||||||||||
| Operating lease liabilities, net of current portion | 4,921 | 5,365 | ||||||||||||||
| Deferred revenue, net of current portion | 3,454 | 3,297 | ||||||||||||||
| Other long-term liabilities | 1,629 | 1,547 | ||||||||||||||
| Total liabilities | 36,021 | 41,133 | ||||||||||||||
| Commitments and contingencies | ||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||
| Preferred stock, | — | — | ||||||||||||||
| Common stock, | 5 | 4 | ||||||||||||||
| Additional paid-in capital | 671,986 | 657,140 | ||||||||||||||
| Accumulated other comprehensive income (loss) | (390 | ) | 403 | |||||||||||||
| Accumulated deficit | (415,235 | ) | (369,937 | ) | ||||||||||||
| Total stockholders’ equity | 256,366 | 287,610 | ||||||||||||||
| Total liabilities and stockholders’ equity | $ | 292,387 | $ | 328,743 | ||||||||||||
| Beta Bionics, Inc. | ||||||||||||||||
| Net Sales by Channel (unaudited) | ||||||||||||||||
| Table C | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| (In thousands) | June 30, | June 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| DME channel: | ||||||||||||||||
| iLet(1) | $ | 12,651 | $ | 13,414 | $ | 22,740 | $ | 23,042 | ||||||||
| Single-use products | 7,762 | 5,230 | 14,596 | 9,429 | ||||||||||||
| Total DME channel | 20,413 | 18,644 | 37,336 | 32,471 | ||||||||||||
| PBP channel: | ||||||||||||||||
| iLet(1) | 221 | 205 | 686 | 711 | ||||||||||||
| Single-use products | 11,379 | 4,389 | 21,617 | 7,695 | ||||||||||||
| Total PBP channel | 11,600 | 4,594 | 22,303 | 8,406 | ||||||||||||
| Total net sales | $ | 32,013 | $ | 23,238 | $ | 59,639 | $ | 40,877 | ||||||||
| (1)iLet includes the over-time recognition software updates and mobile app access. | ||||||||||||||||
| Beta Bionics, Inc. | ||||||||||||||||
| Reconciliation of GAAP versus Non-GAAP Financial Results (unaudited) | ||||||||||||||||
| Table D | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| (In thousands) | June 30, | June 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net loss | $ | (23,403 | ) | $ | (16,869 | ) | $ | (45,298 | ) | $ | (45,525 | ) | ||||
| Add: | ||||||||||||||||
| Depreciation expense | 709 | 347 | 1,294 | 650 | ||||||||||||
| Stock-based compensation expense | 7,016 | 4,799 | 12,422 | 7,603 | ||||||||||||
| Interest income | (2,177 | ) | (3,005 | ) | (4,553 | ) | (5,441 | ) | ||||||||
| Income tax expense | 2 | 2 | 2 | 2 | ||||||||||||
| Litigation settlement and other related expense | 135 | 200 | 135 | 200 | ||||||||||||
| Quality system remediation(1) | 62 | — | 624 | — | ||||||||||||
| Change in fair value of warrant liabilities | — | — | — | 12,450 | ||||||||||||
| Adjusted EBITDA | $ | (17,656 | ) | $ | (14,526 | ) | $ | (35,374 | ) | $ | (30,061 | ) | ||||
| (1)Amounts presented reflect the same category of expenses previously labeled "Other non-recurring" in our Form 10-K for the year ended December 31, 2025. These expenses relate to our one-time remediation efforts in response to the FDA Form 483 and Warning Letter, including contractor support and the various updates to our quality system to meet FDA expectations. | ||||||||||||||||
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.
